Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Rendu Biotechnology CoSHSE:688193 -1.31%63 3-Year ROIIC % is 91.42 as of Dec. 2025, which is 510% above its 10-year median of 14.99. GuruFocus rates SHSE:688193 with a GF Score™ of 63/100 and a GF Value™ of ¥34.69 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Shanghai Rendu Biotechnology Co ranks better than 80.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Shanghai Rendu Biotechnology Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 91.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:688193's 3-Year ROIIC % is ranked better than 80.79% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs SHSE:688193: 91.42
Shanghai Rendu Biotechnology Co (SHSE:688193) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Shanghai Rendu Biotechnology Co 3-Year ROIIC % Related Terms
Shanghai Rendu Biotechnology Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Rendu Biotechnology Co 3-Year ROIIC % Chart
SHSE:688193 vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rendu Biotechnology Co 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Shanghai Rendu Biotechnology Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Shanghai Rendu Biotechnology Co (SHSE:688193) has a 3-Year ROIIC % of 91.42 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai Rendu Biotechnology Co and its competitors. This is 510% above median its historical median of 14.99. According to the industry distribution chart, Shanghai Rendu Biotechnology Co ranks #39 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 19.2%.
Is Shanghai Rendu Biotechnology Co's 3-Year ROIIC % too high?
Shanghai Rendu Biotechnology Co's current 3-Year ROIIC % of 91.42 is 510% above median its 10-year median of 14.99. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Shanghai Rendu Biotechnology Co's value of 91.42 is 41454.5% above this industry median. Based on the distribution chart, Shanghai Rendu Biotechnology Co ranks #39 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Rendu Biotechnology Co has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rendu Biotechnology Co's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Rendu Biotechnology Co ranks #39 out of 203 companies for 3-Year ROIIC %. This places Shanghai Rendu Biotechnology Co in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Shanghai Rendu Biotechnology Co's value of 91.42 is 41454.5% above this benchmark. While the company's 10-year median is 14.99 vs. the industry median of 0.22, Shanghai Rendu Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Rendu Biotechnology Co's current 3-Year ROIIC % of 91.42 is 41454.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai Rendu Biotechnology Co and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Rendu Biotechnology Co's current 3-Year ROIIC % is 91.42, which is 510% above median its own 10-year median of 14.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rendu Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co (SHSE:688193) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥34.69, compared to a current price of ¥48.78 — trading 40.6% above its estimated fair value. The current 3-Year ROIIC % is 91.42, which is 510% above median its 10-year median of 14.99 and 41454.5% above the Medical Diagnostics & Research industry median of 0.22. Shanghai Rendu Biotechnology Co's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Shanghai Rendu Biotechnology Co (SHSE:688193), the current 3-Year ROIIC % is 91.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rendu Biotechnology Co (SHSE:688193) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co stock appears to be overvalued.
The current stock price of ¥48.78 is trading 40.6% above its estimated GF Value™ of ¥34.69.
GuruFocus considers Shanghai Rendu Biotechnology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688193:
3-Year ROIIC %: 91.42 (510% above median its 10-year median of 14.99)
GF Value™: ¥34.69 vs. price of ¥48.78 (40.6% above fair value)
Industry Position: 41454.5% above the Medical Diagnostics & Research median (#39 of 203)
No single metric tells the full story. See the SHSE:688193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.
63GF Score
Get the complete analysis for SHSE:688193
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688193 has been successfully added to your 
